Jitendar K Sharma1, Umesh Gupta2, Greeshma Gopalan3, Keerthan RM3 and Kavita Kachroo4*
1MD & CEO/ ED, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India
2Professor, Head of Mats School of Business Studies, MATS Institute of Management and Entrepreneurship, Bangalore, India
3Scientist -A, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India 4Scientist -D, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India
*Corresponding Author: Kavita Kachroo, Scientist -D, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India.
Received: November 22, 2021; Published: December 29, 2021
Introduction: Ever since the first case was reported in December, in China, Coronavirus disease 2019 (COVID-19) has spread over 218 countries and the casualty prediction of the third wave in India. Making it an absolute necessity for a rapid and accurate detection and diagnosis of the infection for prevention and containment of the disease. Molecular testing (RT-PCR) is considered to be the gold standard for COVID-19 diagnosis is considered accurate.
Methods: The primary COVID-19 diagnosis is done by Polymerase Chain Reaction (PCR) testing. The most common method used for identifying the genetic material from the SARS-CoV-2 is the real-time polymerase chain reaction RT-PCR. A decision analytical model was prepared for RT-PCR testing for COVID-19 diagnosis by selecting three Made in India diagnostic kits (RT-PCR-X, Y and Z) using Tree Age Pro software.
Results: From the economic evaluation, NMB (Net Monitory Benefit) for RT-PCR Y being ₹ 45,43,740 higher and is the most cost-effective intervention as it saves more money compared to other interventions per DALY averted.
Conclusion: Incremental cost-effectiveness ratio (ICER) was calculated, and it is identified that RT-PCR Y is cost effective at ₹ 850 per DALY averted.
PROSPERO ID: PROSPERO CRD42021237539.
Keywords: Cost-effectiveness; COVID-19; Real-time Polymerase Chain Reaction; RT-PCR Kits
Citation: Jitendar K Sharma., et al. “ Economic Analysis of Covid-19 Diagnostic Kits in India”. Acta Scientific Paediatrics 5.1 (2022): 02-08.
Copyright: © 2022 Jitendar K Sharma., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.